John R. Woolfrey and G. Scott Weston Pages 1527 - 1545 ( 19 )
The recent success of the first FDA-approved small-molecule tyrosine kinase inhibitor Gleevec (STI-571, imatinib mesylate) in the treatment of chronic myelogenous leukemia (CML) has focused attention on the potential therapeutic usefulness of inhibitors of other kinase targets. This review shall highlight recent applications of computational chemistry methods, comprising both ligand-based and structure-based approaches, in the discovery and design of kinase inhibitors. In particular, we will focus on ATP-competitive inhibitors of selected kinase targets of therapeutic importance.
kinase inhibitor,gleevec,imatinib mesylate,cml,chronic myelogenous leuremig,comfa,comsia
, Millennium Pharmaceuticals, Inc., 256 East Grand Avenue, South San Francisco, CA94080, USA